These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26905224)

  • 1. Safety and cardiovascular effects of mineralocorticoid receptor antagonists for patients receiving hemodialysis: a systematic review and meta-analysis.
    Zhao Y; Yan B; Zhao Z; Wang S; Weng X
    Ren Fail; 2016; 38(4):589-99. PubMed ID: 26905224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis.
    Chen KT; Kang YN; Lin YC; Tsai IL; Chang WC; Fang TC; Wu MS; Kao CC
    Clin J Am Soc Nephrol; 2021 Jun; 16(6):916-925. PubMed ID: 34117083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials.
    Ng KP; Arnold J; Sharif A; Gill P; Townend JN; Ferro CJ
    J Renin Angiotensin Aldosterone Syst; 2015 Sep; 16(3):599-613. PubMed ID: 25784710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
    Quach K; Lvtvyn L; Baigent C; Bueti J; Garg AX; Hawley C; Haynes R; Manns B; Perkovic V; Rabbat CG; Wald R; Walsh M
    Am J Kidney Dis; 2016 Oct; 68(4):591-598. PubMed ID: 27265777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence.
    Georgianos PI; Vaios V; Eleftheriadis T; Zebekakis P; Liakopoulos V
    Curr Vasc Pharmacol; 2017; 15(6):599-606. PubMed ID: 28155610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis.
    Lu R; Zhang Y; Zhu X; Fan Z; Zhu S; Cui M; Zhang Y; Tang F
    Int Urol Nephrol; 2016 Sep; 48(9):1499-509. PubMed ID: 27193436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis.
    Baker WL; White WB
    Ann Pharmacother; 2012 Jun; 46(6):889-94. PubMed ID: 22669801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of mineralocorticoid receptor antagonists in postmyocardial infarction patients with or without left ventricular dysfunction: A meta-analysis of randomized controlled trials.
    Xu Y; Qiu Z; Yang R; Wu Y; Cheng X
    Medicine (Baltimore); 2018 Dec; 97(51):e13690. PubMed ID: 30572494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis.
    Chen Q; Liang Y; Yan J; Du Y; Li M; Chen Z; Zhou J
    Diabetes Res Clin Pract; 2023 Jan; 195():110210. PubMed ID: 36509181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of low-dose mineralocorticoid receptor antagonists in dialysis patients: A meta-analysis.
    Zhu Y; Liu Y; Cai R; Zheng D; Liang X; Tao M; Jin J; Li Y; He Q
    Medicine (Baltimore); 2021 Feb; 100(8):e24882. PubMed ID: 33663116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa).
    Hammer F; Krane V; Störk S; Röser C; Hofmann K; Pollak N; Allolio B; Wanner C
    Nephrol Dial Transplant; 2014 Feb; 29(2):400-5. PubMed ID: 24166468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety.
    Bomback AS
    Blood Purif; 2016; 41(1-3):166-70. PubMed ID: 26765793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis.
    Berbenetz NM; Mrkobrada M
    BMC Cardiovasc Disord; 2016 Dec; 16(1):246. PubMed ID: 27905877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
    Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ; Wald R
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1602-8. PubMed ID: 26138259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials.
    Li X; Qi Y; Li Y; Zhang S; Guo S; Chu S; Gao P; Zhu D; Wu Z; Lu L; Shen W; Jia N; Niu W
    Circ Heart Fail; 2013 Mar; 6(2):156-65. PubMed ID: 23400891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists.
    Suthar SD; Middleton JP
    Semin Dial; 2016; 29(1):52-61. PubMed ID: 26242304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Mineralocorticoid Receptor Blockade on Arterial Stiffness and Endothelial Function: A Meta-Analysis of Randomized Trials.
    Sakima A; Arima H; Matayoshi T; Ishida A; Ohya Y
    Hypertension; 2021 Mar; 77(3):929-937. PubMed ID: 33461316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid Receptor Antagonist Use in Heart Failure With Reduced Ejection Fraction and End-Stage Renal Disease Patients on Dialysis: A Literature Review.
    Bhinder J; Patibandla S; Gupta CA; Levine A; Gass AL; Lanier GM
    Cardiol Rev; 2020; 28(3):107-115. PubMed ID: 31985521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials.
    Chen Y; Wang H; Lu Y; Huang X; Liao Y; Bin J
    BMC Med; 2015 Jan; 13():10. PubMed ID: 25598008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients.
    Feniman-De-Stefano GM; Zanati-Basan SG; De Stefano LM; Xavier PS; Castro AD; Caramori JC; Barretti P; Franco RJ; Martin LC
    Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):158-67. PubMed ID: 26116627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.